Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to $131.8 million.

  • Therapeutics' Net Cash Flow rose 2080.35% to $131.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.3 million, marking a year-over-year increase of 1332.89%. This contributed to the annual value of $122.3 million for FY2024, which is 1332.89% up from last year.
  • According to the latest figures from Q4 2024, Therapeutics' Net Cash Flow is $131.8 million, which was up 15,918.47% from $823,000 recorded in Q3 2024.
  • In the past 5 years, Therapeutics' Net Cash Flow registered a high of $131.8 million during Q4 2024, and its lowest value of -$62.6 million during Q2 2020.
  • Moreover, its 3-year median value for Net Cash Flow was $4.2 million (2023), whereas its average is $12.1 million.
  • As far as peak fluctuations go, Therapeutics' Net Cash Flow crashed by 867.16% in 2021, and later spiked by 4,337.88% in 2022.
  • Over the past 5 years, Therapeutics' Net Cash Flow (Quarterly) stood at $4.7 million in 2020, then slumped by 867.16% to -$36.0 million in 2021, then soared by 131.25% to $11.2 million in 2022, then plummeted by 159.23% to -$6.7 million in 2023, then skyrocketed by 2,080.35% to $131.8 million in 2024.
  • Its last three reported values are $131.8 million in Q4 2024, $823,000 for Q3 2024, and -$8.2 million during Q2 2024.